Yesterday, Sept. 10, 2015, 91 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $188.49 to $4,934,712.00.

Highlighted Stocks Traded by Insiders:

Enanta Pharmaceuticals (ENTA) - FREE Research Report

Mellett Paul J, who is Treasurer and CFO at Enanta Pharmaceuticals, sold 7,500 shares at $39.55 on Sept. 10, 2015. Following this transaction, the Treasurer and CFO owned 67,897 shares meaning that the stake was reduced by 9.95% with the 7,500-share transaction.

The shares most recently traded at $39.89, up $0.34, or 0.84% since the insider transaction. Historical insider transactions for Enanta Pharmaceuticals go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 3,750
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 22,500
  • 24-Week # shares bought: 2,400
  • 24-Week # shares sold: 76,500

The average volume for Enanta Pharmaceuticals has been 325,700 shares per day over the past 30 days. Enanta Pharmaceuticals has a market cap of $744.8 million and is part of the health care sector and drugs industry. Shares are down 21.18% year-to-date as of the close of trading on Thursday.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the infectious disease field in the United States. The company has a P/E ratio of 11.2. Currently, there are 3 analysts who rate Enanta Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENTA - FREE

TheStreet Quant Ratings

rates Enanta Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, poor profit margins and weak operating cash flow. Get the full

Enanta Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Skullcandy (SKUL) - FREE Research Report

Alden Rick, who is Director at Skullcandy, sold 25,000 shares at $6.79 on Sept. 10, 2015. Following this transaction, the Director owned 933,597 shares meaning that the stake was reduced by 2.61% with the 25,000-share transaction.

The shares most recently traded at $6.58, down $0.21, or 3.19% since the insider transaction. Historical insider transactions for Skullcandy go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 42,850
  • 12-Week # shares bought: 17,000
  • 12-Week # shares sold: 42,850
  • 24-Week # shares bought: 17,000
  • 24-Week # shares sold: 42,850

The average volume for Skullcandy has been 198,700 shares per day over the past 30 days. Skullcandy has a market cap of $190.2 million and is part of the consumer goods sector and consumer durables industry. Shares are down 28.18% year-to-date as of the close of trading on Thursday.

Skullcandy Inc. designs, markets, and distributes audio and gaming headphones, earbuds, speakers, and other accessories under the Skullcandy, Astro Gaming, and 2XL brands in the United States and internationally. The company has a P/E ratio of 26.8. Currently, there are 6 analysts who rate Skullcandy a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SKUL - FREE

TheStreet Quant Ratings

rates Skullcandy as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, unimpressive growth in net income and weak operating cash flow. Get the full

Skullcandy Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Civeo (CVEO) - FREE Research Report

Dodson Bradley J, who is Director at Civeo, bought 150,000 shares at $1.88 on Sept. 10, 2015. Following this transaction, the Director owned 701,476 shares meaning that the stake was boosted by 27.2% with the 150,000-share transaction.

Steininger Frank, who is Officer at Civeo, bought 40,000 shares at $1.89 on Sept. 10, 2015. Following this transaction, the Officer owned 169,274 shares meaning that the stake was boosted by 30.94% with the 40,000-share transaction.

The shares most recently traded at $1.78, down $0.11, or 6.29% since the insider transaction. Historical insider transactions for Civeo go as follows:

  • 4-Week # shares bought: 91,600
  • 4-Week # shares sold: 8,028
  • 12-Week # shares bought: 91,600
  • 12-Week # shares sold: 8,028
  • 24-Week # shares bought: 91,600
  • 24-Week # shares sold: 8,028

The average volume for Civeo has been 1.7 million shares per day over the past 30 days. Civeo has a market cap of $184.8 million and is part of the services sector and diversified services industry. Shares are down 54.01% year-to-date as of the close of trading on Thursday.

Civeo Corporation provides remote site accommodations for the natural resource industry in Australia, Canada, and the United States. The stock currently has a dividend yield of 14.61%. Currently, there are 2 analysts who rate Civeo a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CVEO - FREE

TheStreet Quant Ratings

rates Civeo as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Civeo Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.